Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) have earned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, twelve have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $110.6154.

SLNO has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $120.00 price target (up from $110.00) on shares of Soleno Therapeutics in a research report on Tuesday, January 20th. Wells Fargo & Company restated an “overweight” rating and set a $114.00 price objective (up from $106.00) on shares of Soleno Therapeutics in a research note on Tuesday, January 20th. Zacks Research downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Wolfe Research set a $60.00 target price on Soleno Therapeutics in a report on Monday, January 12th. Finally, Robert W. Baird set a $107.00 price target on Soleno Therapeutics in a research note on Tuesday, January 13th.

Institutional Trading of Soleno Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Soleno Therapeutics by 1.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock worth $1,242,000 after purchasing an additional 189 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Soleno Therapeutics in the second quarter valued at approximately $25,000. Avanza Fonder AB grew its stake in shares of Soleno Therapeutics by 11.2% during the fourth quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock worth $148,000 after buying an additional 323 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Soleno Therapeutics by 11.9% during the third quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock worth $216,000 after buying an additional 340 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its stake in shares of Soleno Therapeutics by 2.4% in the 3rd quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock valued at $1,055,000 after acquiring an additional 360 shares during the last quarter. Institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Trading Up 4.7%

SLNO stock opened at $41.01 on Thursday. Soleno Therapeutics has a 52 week low of $36.67 and a 52 week high of $90.32. The company has a market capitalization of $2.20 billion, a PE ratio of -22.29 and a beta of -3.16. The company’s 50-day simple moving average is $43.01 and its 200 day simple moving average is $53.97. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.88 and a current ratio of 16.08.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million during the quarter, compared to analyst estimates of $88.55 million. As a group, sell-side analysts anticipate that Soleno Therapeutics will post -3.72 earnings per share for the current year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.